Gastroesophageal Reflux Disease
Updated: 02/21/2006

References

Baker ME. Licorice and enzymes other than 11 beta-hydroxysteroid dehydrogenase: An evolutionary perspective. Steroids. 1994 Feb;59(2):136–41.

Bateman DN, Colin-Jones D, et al. Mortality study of 18 000 patients treated with omeprazole. Gut. 2003 Jul;52(7):942–6.

Blot WJ, Li JY, et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993 Sep 15;85(18):1483–92.

Bollschweiler E, Wolfgarten E, et al. Vitamin intake and risk of subtypes of esophageal cancer in Germany. J Cancer Res Clin Oncol. 2002 Oct;128(10):575–80.

Bushman JL. Green tea and cancer in humans: A review of the literature. Nutr Cancer. 1998;31(3):151–9.

Chen H, Tucker KL, et al. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer. 2002b;42(1):33–40.

Chen H, Ward MH, et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr. 2002a Jan;75(1):137–44.

Cheng KK, Day NE. Nutrition and esophageal cancer. Cancer Causes Control. 1996 Jan;7(1):33–40.

Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut. 2003 Apr;52(4):464–70.

Collings KL, Rodriguez-Stanley S, et al. Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control. Aliment Pharmacol Ther. 2002 Dec;16(12):2029–35.

Colombo P, Mangano M, et al. Effect of calories and fat on postprandial gastro-oesophageal reflux. Scand J Gastroenterol. 2002 Jan;37(1):3–5.

DeVault KR. Current management of gastroesophageal reflux disease. Gastroenterologist. 1996 Mar;4(1):24–32.

El-Serag HB, Aguirre TV, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004 Oct;99(10):1877–83.

Farrow DC, Vaughan TL, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000 Mar;11(3):231–8.

Farup PG, Juul-Hansen PH, et al. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol. 2001 Sep;33(3):206–9.

Fossmark G, Johnsen G, et al. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther. 2005 Jan 15;21(2):149–54.

Franceschi S, Bidoli E, et al. Role of macronutrients, vitamins and minerals in the aetiology of squamous-cell carcinoma of the oesophagus. Int J Cancer. 2000 Jun 1;86(5):626–31.

Gao YT, McLaughlin JK, et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst. 1994 Jun 1;86(11):855–8.

Gilani AH, Ghayur MN. Pharmacological basis for the gut stimulatory activity of Raphanus sativus leaves. J Ethnopharmacol. 2004 Dec;95(2–3):169–72.

Gillen D, McKoll KE. Problems associated with the clinical use of proton pump inhibitors. Pharmacol Toxicol. 2001 Dec;89(6):281–6.

Glenn TF. Esophageal cancer: Facts, figures, and screening. Gastroenterol Nurs. 2001 Nov;24(6):271–3.

Hillman LC, Chiragakis L, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett’s oesophagus. Med J Aust. 2004 Apr 19;180(8):387–91.

Jeong SI, Lee S, et al. Methylisogermabullone isolated from radish roots stimulates small bowel motility via activation of acetylcholinergic receptors. J Pharm Pharmacol. 2005 Dec;57(12):1653–9.

Jung KY, Choo YK, et al. Radish extract stimulates motility of the intestine via the muscarinic receptors. J Pharm Pharmacol. 2000 Aug;52(8):1031–6.

Kasper DL, Braunwald E, et al. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Medical Publishing Division; 2005.

Khoury RM, Camacho-Lobato L, et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1999 Aug;94(8):2069-73.

Lagergren J, Bergstrom R, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825–31.

Mark SD, Qiao YL, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst. 2000 Nov 1;92(21):1753–63.

Martin de Argila C. Safety of potent gastric acid inhibition. Drugs. 2005;65 Suppl 1:97–104.

Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002 Nov;132(11 Suppl):3467S–3470S. Review.

Mayne ST, Risch HA, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055–62.

Nilsson M, Johnsen R, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003 Jul 2;290(1):66–72.

Nilsson M, Lagergren J. The relation between body mass and gastro-oesophageal reflux. Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1117–23.

Oh TY, Lee JS, et al. Oxidative stress is more important than acid in the pathogenesis of reflux oesophagitis in rats. Gut. 2001 Sep;49(3):364–71.

Pandolfino JE, Kahrilas PJ. Smoking and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000 Aug;12(8):837–42.

Pehl C, Pfeiffer A, et al. Effect of caloric density of a meal on lower oesophageal sphincter motility and gastro-oesophageal reflux in healthy subjects. Aliment Pharmacol Ther. 2001 Feb;15(2):233–9.

Penagini R, Mangano M, et al. Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal sphincter motor function. Gut. 1998 Mar;42(3):330–3.

Qvistad G, Waldum H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol. 2004 May;94(5):202–8.

Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett’s oesophagus. Dig Dis. 2004;22(2):171–80. Review.

Reinke CM, Breitkreutz J, et al. Aluminium in over-the-counter drugs: Risks outweigh benefits? Drug Saf. 2003;26(14):1011–25.

Rudolph RE, Vaughan TL, et al. Serum selenium levels in relation to markers of neoplastic progression among persons with Barrett’s esophagus. J Natl Cancer Inst. 2003 May 21;95(10):750–7.

Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: The NHANES I Epidemiologic Followup Study. First National Health and Nutrition Examination Survey. Ann Epidemiol. 1999 Oct;9(7):424–35.

Ruscin JM, Page RL, et al. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002 May;36(5):812–6.

Scott ML. Essential inorganic elements. In: Scott, ML, ed. Nutrition of Humans & Selected Animal Species. New York: John Wiley & Sons; 1986:388–400.

Shklar G. Mechanisms of cancer inhibition by anti-oxidant nutrients. Oral Oncol. 1998 Jan;34(1):24–9.

Siassi F, Pouransari Z, et al. Nutrient intake and esophageal cancer in the Caspian littoral of Iran: A case-control study. Cancer Detect Prev. 2000;24(3):295–303.

Smit CF, Copper MP, et al. Effect of cigarette smoking on gastropharyngeal and gastroesophageal reflux. Ann Otol Rhinol Laryngol. 2001 Feb;110(2):190–3.

Steinmetz KA, Potter JD. Vegetables, fruit, and cancer. II. Mechanisms. Cancer Causes Control. 1991 Nov;2(6):427–42.

Suleiman UL, Harrison M, et al. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: A case-control study. Eur J Cancer Prev. 2000 Jun;9(3):185–91.

Taylor PR, Li B, et al. Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res. 1994 Apr 1;54(7 Suppl):2029s-31s.

ter HH, Hendriks HJ, et al. Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency? J Pediatr Gastroenterol Nutr. 2001 Sep;33(3):342–5.

Terry P, Lagergren J, et al. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer. 2000 Sep 1;87(5):750–4.

Topazian M. Gastrointestinal endoscopy. In: Braunwald E, Fauci AS, et al, eds. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 2005:1635–42.

Trudgill NJ, Smith LF, et al. Impact of smoking cessation on salivary function in healthy volunteers. Scand J Gastroenterol. 1998 Jun;33(6):568–71.

Vanderhoff BT, Tahboub RM. Proton pump inhibitors: An update. Am Fam Physician. 2002 Jul 15;66(2):273–80.

van Marle J, Aarsen PN, et al. Deglycyrrhizinised liquorice (DGL) and the renewal of rat stomach epithelium. Eur J Pharmacol. 1981 Jun 19;72(2–3):219–25.

Wise J, Conklin JL. Gastroesophageal reflux disease and baclofen: Is there a light at the end of the tunnel? Curr Gastroenterol Rep. 2004 Jun;6(3):213–9. Review.

Wolfgarten E, Rosendahl U, et al. Coincidence of nutritional habits and esophageal cancer in Germany. Onkologie. 2001 Dec;24(6):546–51.

Yano S, Harada M, et al. Antiulcer activities of glycyrrhetinic acid derivatives in experimental gastric lesion models. Chem Pharm Bull (Tokyo). 1989 Sep;37(9):2500–4.

Zhang Q, Lehmann A, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002 Jan;50(1):19–24.

Zheng W, Sellers TA, et al. Retinol, antioxidant vitamins, and cancers of the upper digestive tract in a prospective cohort study of postmenopausal women. Am J Epidemiol. 1995 Nov 1;142(9):955–60.